International Stem
Cell Corp., a biotech company developing novel stem cell-based therapies,
announced this morning that it has entered into a twelve-month research
agreement with Rohto Pharmaceutical Co., Ltd., a global Japanese pharmaceutical
company that develops new technology for the medical and cosmetics markets with
approximately $1.3 billion in consolidated annual sales. Founded in 1899, Rohto
today has products available in more than 150 countries.
Rohto has agreed to
evaluate stem cell-derived human cells owned and provided by ISCO in a number
of pre-clinical animal models. If the research is successful and the parties
agree on remaining terms, it is anticipated that a definitive license agreement
will be signed at the end of this research agreement. Certain key terms of such
a license agreement, including the target disease areas and intellectual
property rights, have already been defined in the research agreement.
“We are delighted to
have such an outstanding company work with us, and we believe that the
potential for this agreement is significant,” stated Dr. Simon Craw, EVP of Business
Development at ISCO. “Under the terms of the agreement Rohto will begin working
with our cells immediately and if the program is successful we may move to the
next stage, signing a definitive license agreement. Such an agreement would
significantly enhance our standing in a number of ways. Firstly, having
diligently built up our scientific strength and patent portfolio over the last
few years, it would both validate our research as well as our ability to
generate licensing revenue from our proprietary platform. Secondly, by
expanding the use of our technology into new areas beyond that which we can
address alone, it would add value to the Company.”
Under the agreement
ISCO will provide a number of differentiated human cells derived from the
company’s collection of pluripotent human stem cells known as UniStemCell™. The
Company has a track record of successfully demonstrating that human cells
derived from UniStemCell™ are effective in animal models of various diseases
and have the potential to be used as a basis for developing human therapies.
ISCO has adopted this approach successfully with a number of academic
collaborators in the past.
For more information
on International Stem Cell Corp., please visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment